Multifocal inflammatory leukoencephalopathy associated with levamisole therapy

David W. Kimmel, Eelco F.M. Wijdicks, Moses Rodriguez

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


cerebral demyelinating disease developed in a patient during adjuvant therapy with levamisole for malignant melanoma. This patient had no evidence of previous neurologic disease. Levamisole was administered for 5 weeks (total dose, 1,500 mg). Over a period of 3 weeks, the patient became progressively confused and ataxic. MRI with gadolinium enhancement demonstrated prominent multifocal enhancing white matter lesions. CSF examination revealed an inflammatory profile. After discontinuation of treatment with levamisole and a short course of corticosteroid therapy, the patient's condition dramatically improved. MRI also indicated improvement. Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5–fluorouracil and levamisole may have been caused at least partly by levamisole.

Original languageEnglish (US)
Pages (from-to)374-376
Number of pages3
Issue number2
StatePublished - Feb 1995

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Multifocal inflammatory leukoencephalopathy associated with levamisole therapy'. Together they form a unique fingerprint.

Cite this